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Abstract
Purpose Treatment protocols in pediatric oncology have
historically known high accrual rates, up to 94 %. Accrual
for supportive care studies on the other hand appears to be a
challenge. The aim of this study was to search for reasons
explaining this poor accrual and for possible interventions to
improve patient enrolment.
Methods The failure screen log of our supportive care study
(the Aristocaths study) was analyzed, and subsequently, a
literature search was performed.
Results The literature search (1985–2011) revealed three
factors that can influence accrual. Firstly, study implemen-
tation and patient enrolment can be facilitated by appointing
a dedicated clinical investigator in all participating centers
and by facilitating clinical research nurses. Furthermore,
adequate and tailor-made information is required for fami-
lies to make a well-informed decision regarding study par-
ticipation. Lastly, sufficient time should be assured for the
process of decision making, especially since the number of
eligible studies is increasing rapidly. Concerning our study,
all three elements were met, but the most striking finding
was the presumed burden of study participation by the
majority of parents (82 %) as the main argument against
randomization.
Conclusions Accrual of pediatric oncology patients in sup-
portive care studies is challenging. Nevertheless, well-
designed randomized controlled trials in supportive care will
be essential for the improvement of pediatric cancer care.
Therefore, we will need to increase awareness through
(inter)national supportive care working groups regarding
the need for supportive care trials and stimulate accrual
when such trials are open.
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Introduction
Participation in clinical trials clearly benefits the outcome of
oncology patients. Pediatric oncology has historically
known high accrual rates for treatment protocols, and in
the past decades, extensive research and inclusion in treat-
ment protocols has led to an increase in 10-year survival
from 10 to 80 % for children with cancer [1–4]. Accrual for
other types of clinical trials on the other hand, such as
nontherapeutic trials or supportive care trials, appears to be
a challenge in the same patient population [5]. An explana-
tion for this disparity might be the fact that these studies do
not involve the cancer treatment itself but supportive care
interventions needed during and after treatment. It is well
known that at the start of treatment, both parents and the
child receive a lot of information on the treatment and
complications that can occur. This causes emotional distress
making it difficult to realize what is coming. In the current
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pediatric oncology practice, the child is eligible to more than
one study at the same time. In our center for example,
children diagnosed with acute lymphoblastic leukemia
are eligible to five different studies: one treatment proto-
col and four supportive care or non-treatment protocols.
Because decisions are often required within the first few
days after diagnosis, some studies are mentioned in the
same consultation as the actual diagnosis. All studies are
approved for by the medical ethical committee. All are
clinically relevant and aimed to improve cancer treat-
ment. But how much information can one handle? Which
study has priority?
To gain insight in the reasons for the poor accrual in
supportive care studies, we analyzed the failure screen
log of our supportive care study: the Aristocaths. Since
the start of this study, we have registered reasons to
refuse study participation in the failure screen log. Sub-
sequently, we performed a literature search to search for
reasons explaining this accrual rate and focus on points
of improvement.
The Aristocaths study
The Aristocaths study (NTR 1275) started in The Netherlands
in 2007. This study investigates the role of 70 % ethanol locks
in the prevention of catheter-related infections in pediatric
cancer patients with tunneled central venous catheters (CVC)
[6]. However, over the past 3 years, accrual turned out to be
lower than expected, i.e., about 50 % of the projected accrual.
Failure screen log
Since the start of the Aristocaths study, eligible patients were
registered at all four participating study sites. If patients were
eligible but decided not to participate, the reason for their
refusal was registered in the failure screen log. The study is
still ongoing; failures reported in this study have been
registered between October 2007 and December 2010.
Between October 2007 and December 2010, 458 patients
were diagnosed in the four participating pediatric oncology
centers (Fig. 1). Sixty-two patients (14 %) were excluded for
the following reasons: (1) age less than 1 year, (2) docu-
mented infection at the time of catheter insertion, (3) a
previous central venous catheter, or (4) because study intro-
duction took longer than a month. Since most catheter-
related infections occur within 45 days, randomization and
placement of the first study lock shortly after CVC place-
ment is aimed for.
Considerations not to participate were grouped as
“parents’ decision” or “physicians’ decision.” Failure rates
ranged between 37 and 61 %, with the lowest rate in the
initiating center (Table 1). In this center (Table 1, center nr.
1), these considerations were registered with a full text
description of the reason for refusal. In total, 57/182 failures
(31 %) occurred in this center. In 44/57 (77 %) failures, the
decision not to participate in the Aristocaths study was made
by the parents. Main argument for 36/44 (82 %) families
was the potential burden of study participation. This burden
was either explained as an actual time burden; 2-h waiting
for the study lock to take place, or as a psychological
burden; to take in all new information and make a decision.
Parents expressed the following considerations: “everything
is too much,” “2-h waiting is too much,” and “fear for CVC
manipulation.” Four other families were troubled by the
experimental aspect of participation: “do not want my child
to be used as a guinea pig.” Other considerations were:
“evidence unconvincing,” “enough other children to partici-
pate,” or “risky, side effects are unclear.” In 13/57 (23 %)
failures, the treating oncologist decided not to ask the family
for informed consent: most often because of language diffi-
culties (six patients, 46 %). Other reasons for treating oncol-
ogists to refrain from study introduction were: “palliative
treatment,” “physical condition of the child,” “complicated
treatment history,” and “autistic disorder.”
Failure analysis
Patient accrual in randomized clinical trials is a multifacto-
rial process. Several studies have described factors influenc-
ing accrual rates and employed the following classification:
trial factors, physicians’ perspectives, parents’ perspectives,
and child factors [1, 4, 7]. This classification was used
for evaluation of factors affecting the accrual rate of the
Aristocaths study.
Trial factors
The Aristocaths study is a national multicenter pediatric
oncology study in supportive care and is supported by the
Dutch Childhood Oncology Group, thereby prescribing
study participation nationwide. Yearly, approximately 600
newly diagnosed patients are treated in The Netherlands.
With an estimated accrual rate of 50 %, randomization of
200 patients in both arms was calculated to be easily
achieved within 3 years. Unfortunately, understaffing of
research facilitating personnel and organizational issues
have made implementation of the Aristocaths study impos-
sible for two out of six oncology centers, thereby leading to
smaller numbers of eligible patients and longer study dura-
tion. This can in part be attributed to the study itself; imple-
mentation of the Aristocaths study is labor intensive and
requires a lot of effort by the clinical research team, con-
stantly monitoring the study patients for lock eligibility and
the occurrence of infectious or serious adverse events.
3150 Support Care Cancer (2012) 20:3149–3153
Limited staff and funding are common problems, especially
for supportive care studies such as the Aristocaths study
since these studies are given lower priority than therapeutic
protocols [5].
Since the incidence of cancer in children is rare, national
and international cooperation in multicenter trials is required.
Such cooperation can be a logistic and methodological chal-
lenge: to obtain approval from different medical ethical com-
mittees, to organize research facilitating personnel, to conform
to good clinical practice legislation, and to motivate clinicians
about the relevance of the research question. Carter et al.
reported successful interventions in nontherapeutic Childhood
Oncology Group studies, such as the implementation of coor-
dinating centers, principal investigators and monetary reim-
bursements, leading to improved study execution and patient
enrolment [5]. Although the abovementioned interventions
were realized for the Aristocaths study, accrual remained poor
because less centers were involved in this study as intended.
Physicians’ perspectives
Disbelief in the benefit of study participation by treating
physicians has been mentioned one of the major barriers in
adult medicine [8–10]. Caldwell et al. investigated the atti-
tudes of 21 pediatric physicians towards randomized con-
trolled trials in children. Physicians mentioned feeling
uncomfortable with the chance of randomization to the
placebo arm, particularly for terminally ill patients. Others
thought disclosure of uncertainty in regard to the best avail-
able treatment would lead to mistrust by parents, expecting
their doctor to know all the answers [11].
In case of the Aristocaths study, the 50 % chance of being
randomized to the placebo arm with 2-h waiting without
treatment benefits was a strong argument for both physi-
cians and families against study participation.
Parents’ perspectives
Parents are responsible to decide upon trial participation in
their child’s best interest, with or without the assent of the
child itself. A truly informed decision is difficult and is even
considered impossible by some [12]. The key ingredient for
such decisions is the availability of adequate information,
both by personal communication and in writing [13]. Never-
theless, Kodish et al. reported that despite oral and written
explanation, half of the parents in their cohort did not under-
stand the principle of randomization. They observed
explanations of randomization and parental understanding
afterwards in 137 informed consent consultations. Al-
though 83 % of physicians explained the principle of
randomization, 50 % of parents did not comprehend this
key aspect of their decision [14]. Partly, this knowledge
gap can be attributed to the emotional distress parents
experience, confining them from taking in new and com-
plex information. Furthermore, patient informed consent
forms (PIFs) often contain too many legal details, required
by good clinical practice guidelines, which makes the PIFs
unreadable. What is the optimal approach for study intro-
duction and how can adequate information be delivered?
Eder et al. interviewed 140 parents of children who had
been offered participation in a randomized clinical trial for
the treatment of their acute leukemia. In this study, parents
expressed the desire for sufficient time to make a decision
and to consult others. Furthermore, information should be
tailor made and adjusted to parents’ desires [15]. Parents
also advocated the need for repetition, honest and empathic
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Fig. 1 Flowchart of patient
selection. Analysis of patients
diagnosed between 2007 and
2010 in four participating
centers and registered in the
failure screen log. Full text
registrations were kept for the
initiating center (nr. 1) only
Table 1 Number of eligible patients, number of patients excluded
from randomization and failure rates, specified per participating center
Center Eligible Excluded Failure
N N (%) N (%)
1. 167 12/167 (7.2) 57/155 (37)
2. 88 15/88 (17) 29/73 (40)
3. 162 30/162 (19) 81/132 (61)
4. 41 5/41 (12) 15/36 (42)
Total 458 62/458 (14) 182/396 (46)
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communication, with limited jargon and plenty of opportunity
and encouragement to ask questions [13].
Child factors
Child factors differ among age groups: being infants,
(young) children, or young adults. For the first two groups,
decisions concerning treatment are predominantly made by
parents. In the group of adolescents and young adults on the
other hand, decisions are made by the young adult himself
or with the adolescent’s assent. This group, however, repre-
sents the lowest rate of trial participation: Ferrari et al.
reported in 2008 that rates in the age group of 15 to 19 year
olds were lower than in any other 5-year age group below or
above age 35 [16]. Apart from lower trial participation
among adolescents and young adults in general, these
patients often receive their cancer treatment in medical
oncology centers, where accrual rates are lower and clini-
cians are less familiar with pediatric protocols [17]. This
does not account for the Aristocaths study: in The
Netherlands, all pediatric oncology patients (until the age
of 18) are treated in pediatric oncology centers and thus
eligible for study participation. The median age of patients
included in the Aristocaths study was 8.4 years (range, 1.0–
17.6 years) at randomization.
Discussion
Although trial participation in pediatric oncology treat-
ment protocols is excellent, with accrual rates up to
94 %, accrual in supportive care protocols remains a
challenge with accrual rates of less than 50 % [18, 19].
This poor accrual can predominantly be attributed to
trial factors: some trial factors cannot be overcome since
they are part of the study hypothesis. Study participa-
tion by multiple centers can be assisted by the alloca-
tion of an initiating center and principal investigator.
They can facilitate study implementation through study
coordination and provide monetary reimbursements for
research personnel. The principal investigator can in-
crease awareness of the trial and elucidate the relevance
of the trial’s hypothesis. Physicians’ and parents’ per-
spectives are based upon perceived benefits and burdens
of study participation. Considering the Aristocaths study,
parents and physicians will balance the benefit of infec-
tion prevention against the burden of 2-h waiting for
study locks. Therefore, adequate and tailor-made infor-
mation is needed to facilitate a well-informed decision
by family and child. Also, parents should be offered
additional time to make a decision regarding trial par-
ticipation of their child, especially given the current
rapid increase in clinical trials [13].
The necessity and relevance of treatment protocols often
need less explanation compared to supportive care protocols
since they are considered standard of care by most pediatric
oncologists. Nevertheless, morbidity during and after treat-
ment still approaches 40 %, and 1 % of pediatric oncology
patients die of infections or other severe complications [20].
Well-designed randomized controlled trials in supportive
care are of great importance to improve outcome in pediatric
oncology. Unfortunately, many questions concerning sup-
portive care remain unanswered because trials were too
small or prematurely stopped because of poor accrual
[21–23]. Therefore, explanation by principal investigators
alone will not be enough to preserve studies in supportive
care. National and international supportive care working
groups should increase awareness regarding the need for
well-designed randomized controlled trials in supportive
care and stimulate accrual when such trials are open.
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